Cellceutix Corp. has signed a Confidential Disclosure Agreement with a leading research and cancer treatment center in New York City for the licensing of a novel compound with the potential to treat illnesses associated with cancer. The compound is not a drug for tumor regression and could create a new market for Cellceutix.   Cellceutix is a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers an...